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Abstract
Objective UV3 -A/riboflavin cross-linking (CXL) of corneal collagen fibers is an estab-
lished, highly promising therapy for corneal melting in physician-based ophthalmol-
ogy. A prospective pilot study was conducted to demonstrate proof of principle of this
novel method for the treatment of melting corneal ulcers in dogs and cats.
Procedures After obtaining owner consent, CXL was performed in three cats and three
dogs with corneal melting, which either affected the entire corneal surface or was
resistant to conventional antibiotic and anticollagenolytic therapy, or affected parts or
all of the corneal surface. Medical therapy was continued in all patients. The available
follow-up ranged from 2 to 22.5 months and involved slit-lamp examination, fluores-
cein staining, and photographic documentation during all rechecks.
Results Surgical stabilization of the cornea was not necessary in any case, because pro-
gression of corneal melting was arrested in all cases within 1–20 days of CXL treat-
ment. Corneal re-epithelization occurred within 7–40 days in all eyes. At 40 days after
CXL, all eyes presented a quiescent corneal state without signs of active inflammation
and with beginning scar formation. The complications observed in three of the six
animals included a corneal sequestrum, superficial corneal stromal pigmentation, and
bullous keratopathy.
Conclusions This study shows the feasibility of CXL to treat progressive corneal
melting in veterinary patients. CXL may represent a cost-efficient and safe alternative
therapy in the treatment for corneal melting in veterinary ophthalmology. More inves-
tigations comparing the effectivity and complication rate of CXL to those of standard
medical treatment are necessary.
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INTRODUCTION
Cross-linking (CXL) was developed for the treatment of
primary and secondary corneal ectatic diseases: keratoc-
onus, pellucid marginal degeneration, and iatrogenic kera-
tectasia.1–4 These conditions are all characterized by a
distinct decrease in corneal biomechanical stability.
Between 2003 and 2007, additional indications for CXL
were introduced: bullous keratopathy, early Fuchs’ dystro-
phy, and the treatment for noninfectious and infectious
corneal melting.5–11
Corneal melting is caused by the release of endogenous
and exogenous collagenolytic matrix metalloproteinase
(MMP) enzymes and an imbalance between these proteo-
lytic enzymes and the proteinase inhibitors present in the
cornea and precorneal tear film.12,13 An infection often
drives the inflammatory state responsible for corneal
melting, but cannot always be demonstrated.14 Infectious
melting keratitis in people represents a serious and vision-
threatening condition, especially in the developing
countries.15–18 In the veterinary field, infectious melting
keratitis is an even more common condition and occurs
with relative frequency, especially in predisposed
breeds.19,20 There are few corneal pathogens that are
directly associated with primary corneal infections in veter-
inary medicine.21–24
Infectious melting keratitis is typically caused by sec-
ondary bacterial or fungal corneal infections. Secondary
infections are usually facilitated by prior problems that
weaken the cornea’s anatomic barriers and physiologic
defenses such as low corneal sensation, quantitative and
qualitative tear film deficiencies, exposure keratitis,
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trauma, eyelid abnormalities. Such prior problems, topical
medications, and systemic immune-mediated disease may
also lead to melting in the absence of infection by affect-
ing the balance of the healing response through the pro-
duction of collagenolytic agents by resident and
inflammatory cells.25–28
Aggressive treatment with topical antimicrobials to bat-
tle a potential infection and with anticollagenases to
directly counter collagenolysis is indicated to stop pro-
gression of the melting process.12,14 The results of medical
treatment are variable. Several factors including the often
advanced state of the disease at which veterinary patients
are presented to the ophthalmologist, inability of owners
to adequately follow drug therapy, antimicrobial drug
resistance of pathogens29 and problems with patient com-
pliance can negatively influence the course of the disease.
In a significant number of cases, corneal melting leads to
progressive ulceration and even perforation, necessitating
globe stabilizing, tectonic surgery, or enucleation. Some
clinicians and owners might even feel forced to elect
euthanasia over treatment in extreme cases.14,30
Natural collagen cross-links consist of covalent bonds
between the amino side chains of the collagen fibers and
are one of the physiological principles that assure the bio-
mechanical stability of the cornea. The technique of cor-
neal collagen cross-linking with riboflavin and UV-A
irradiation (CXL) is a new treatment modality that was
introduced to clinical use in humans in 1999.4 Riboflavin
(vitamin B2) acts as a photosensitizer when exposed to
UV-A light with a wavelength at the riboflavin absorption
peak of 370 nm. Free radicals introduce additional cross-
links within and between collagen fibers in this process of
photopolymerization, increasing the biomechanical stabil-
ity of the human cornea to a depth of 330 lm.3 The bio-
chemical stability of the cornea is increased by sterical
hindrance of collagenase-binding sites and subsequent
inhibition of the collagenolytic enzyme activity.31 Addi-
tionally, the free radicals induced by CXL directly damage
and destroy microorganisms and lead to apoptosis of cells
in the irradiated area.9,11,32–34
The degree of efficacy and safety of CXL is dependent
on the absorption of UV-A radiation by riboflavin-soaked
corneal tissue, which makes the diffusion of riboflavin
within the cornea and degree of riboflavin saturation of
the superficial stroma crucial to CXL treatment.35 Ribo-
flavin diffuses throughout the entire corneal stroma and
can also be detected in the anterior chamber with a slit-
lamp. A standard CXL treatment protocol as described in
the materials and methods section of this paper led to ke-
ratocyte death up to a depth of approximately 300 lm in
rabbits. The depth of keratocyte loss was directly and pos-
itively correlated with the UV-A irradiance level.34 No
observable toxic effects were present beyond 300 lm. A
similar CXL depth penetration was demonstrated with in
vivo confocal microscopy in a clinical study in humans.36
This maximal treatment depth gave rise to the concept of
riboflavin shielding, an effect that protects all the struc-
tures at deeper levels such as the corneal endothelium, iris,
lens epithelium, lens fibers, and the retina, which are theo-
retically exposed to a safe level of UV radiation.35 Histo-
logic damage to endothelial cells was demonstrated only
when the normal UV radiation dose (UV irradiance of
3 mW/cm2) was exceeded at least twofold in 400-lm-
thick rabbit corneas.37 As UV radiation travels through
the corneal stroma, photons are continuously absorbed by
riboflavin molecules: decreasing the number of photons,
the deeper the irradiation penetrates the tissue. The over-
all energy arriving at the endothelium is thus lowered,
resulting in UV-A irradiance at the level of the endothe-
lium that is less than half of the endothelium’s damage
threshold of 0.36 mW/mm2.35 The combination of ribo-
flavin saturation of the corneal stroma and a minimal cor-
neal stromal thickness of more than 300 lm during
treatment theoretically guarantees the safety of CXL. This
has led to the recommendation that CXL should only be
performed in physician-based ophthalmology if the total
corneal thickness measures at least 400 lm.38
During the last 5 years, several groups have published
studies in humans where CXL was used as an adjuvant
treatment in cases where medical therapy had failed to
control infectious melting keratitis. In all cases published,
CXL led to an arrest of progression of infectious melt-
ing.7,8,39–42
To our knowledge, there are no published descriptions
of the use of CXL in veterinary ophthalmology. This is a
pilot study that investigates and reports the potential
effectiveness of CXL as described for use in humans for
the treatment of keratitis and stromal melting in three cats
and three dogs.
MATERIALS AND METHODS
Animals
Three cats and three dogs with unilateral progressive cor-
neal melting were included in this interventional prospec-
tive study. All treatments were performed at the veterinary
clinical teaching hospital of the Veterinary (Vetsuisse)
Faculty of the University of Zurich, Switzerland, after
obtaining owner consent. All procedures conformed to the
ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research and were in accordance with institu-
tionally approved animal protocols. Table 1 summarizes
the clinical and ocular characteristics of the animals.
Table 2 summarizes the medical treatment given before
referral, between referral and CXL treatment, and after
CXL treatment.
Pretreatment examination
Pretreatment analysis included slit-lamp examination, fluo-
rescein staining, photography, and corneal culture and
sensitivity testing. Culture and sensitivity samples were
collected from all cats and one dog (Dog2). Although all
© 2013 American College of Veterinary Ophthalmologists, Veterinary Ophthalmology, 1–11
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animals had been treated with topical antibiotics prior to
collection of the culture samples, culture and sensitivity
testing was abandoned in two dogs (Dog1 and Dog3) due
to the previously initiated antibiotic therapy. The diagno-
sis of corneal melting was based on a subjective evaluation
of stromal stability/melting activity, including the presence
Table 1. Signalment, pre- and post-CXL-treatment patient characteristics
Patient Breed
Age
(years)
Diameter
of infiltrate
prior to
CXL (mm)
Maximal
ulcer depth
prior to
CXL (%)
Result of
bacteriology
Treatment
prior to
referral
(days)
Treatment
prior to
CXL
(days)*
Stabilization
stroma after
CXL within
(days)†
Complete
epithelial
closure
after (days)‡
Follow-up
(months)
Cat1 European
short hair
8 5 9 4 15–20 No growth 0 15 2 18 17.5
Cat2 European
short hair
11 5 9 7 50 No growth 3 1 4 7 22.5
Cat3 European
short hair
13 11 9 11 75 No growth 4 1 12 15 14
Dog1 Pug 6 5 9 5 50 No bacteriology 0 1 1 13 5
Dog2 Pug 7 11 9 13 50 No growth 2 0 1 40 3
Dog3 Samoyed 13 8 9 7 Superficial
ulcer
No bacteriology 30 2 20 30 2
*Treatment prior to CXL refers to the duration of treatment (in days) received after referral to the veterinary clinical teaching hospital of the
Veterinary (Vetsuisse) Faculty of the University of Zurich, Switzerland, but before undergoing CXL. †All animals were treated with topical and/
or systemic collagenase inhibitors at least until the corneal stroma was judged to be stable, based on the semi-objective evaluation of stromal sta-
bility/melting activity as described in the Materials and Methods.
‡All animals were treated with topical antibiotics until complete epithelial closure had occurred.
Table 2. Summary of medical treatment given before and after CXL treatment
Patient
Medical treatment
Prior to referral Referral – CXL Post-CXL
Cat1 Tobramycin Ofloxacin 0,3% Q1-6H
Oxytetracycline 1% Q4-6H
Atropine 1% once daily
Meloxicam*
Oxytetracycline 1% Q4-6H
K-EDTA 0,36% Q6H
Meloxicam*
L-lysine 500 mg BID
Cat2 Neomycin/polymyxin/bacitracin Tobramycin 0,3% Q2-4H
Oxytetracycline 1% QID
Serum Q2-4H K-EDTA
0,36% Q2-4H
Artificial tear gel Q2-4H Doxycycline†
Meloxicam*
Tobramycin 0,3% Q2-4H
Oxytetracycline 1% QID
Serum Q2-4H
K-EDTA 0,36% Q2-4H
Artificial tear gel Q2-4H
Doxycycline†
Meloxicam*
Cat3 Ciprofloxacin Oxytetracycline 1% QID
K-EDTA 0,36% Q4H
Serum Q4H
Buprenorphine 0.007 mg/kg
QID
Oxytetracycline 1% QID
Ofloxacin 0,3% Q4H
K-EDTA 0,36% Q4H
Doxycycline†
Buprenorphine 0.007 mg/kg
QID
Dog1 Neomycin/polymyxin/gramicidin Q4H
Oxytetracycline 1% QID
K-EDTA 0,36% Q4H
Atropine 1% once daily
Neomycin/polymyxin/gramicidin Q4H
Oxytetracycline 1% QID
K-EDTA 0,36% Q4H
Atropine 1% once daily
Dog2 Tobramycin/dexamethasone Ciprofloxacin Atropine
Vitamin A Dorsolamide (topical) Meloxicam (oral)
Ofloxacin 0,3% Q2-4H
Oxytetracycline 1% TID
Serum Q2-4H
K-EDTA 0,36% Q2-4H
Doxycycline†
Dog3 Neomycin/polymyxin/bacitracin Chloramphenicol
Dexamethasone (topical)
Oxytetracycline 1% TID
K-EDTA 0,36% QID
Oxytetracycline 1% TID
K-EDTA 0,36% QID
5% NaCl ointment QID
*Meloxicam was prescribed once daily at 0.1 mg/kg on day 1 and 0.05 mg/kg afterward. †Doxycycline was prescribed at 5 mg/kg BID on day 1,
once daily afterward.
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of cellular infiltrates, the perceived stability of the stroma,
the presence of changes in corneal contour and ulcer
depth, and the presence of malacic corneal material in the
ulcer area. Cellular infiltrates were present in all affected
corneas, and although corneal thickness could not be mea-
sured reliably over the area of the infiltrates, slit-lamp
examination showed the loss of corneal stroma in all cases
(Table 1).
Cat1, an eight-year-old male castrated European Short-
hair, presented with a history of bilateral, chronic, inter-
mittent eye problems, which had been responsive to
topical tobramycin treatment according to the owner. No
further medications were given prior to referral. Upon
examination, a corneal ulcer with yellow cellular infiltrates
and 10% loss of stroma was observed in the left eye (OS).
No further (peri)ocular abnormalities that might account
for the melting keratitis were observed. Between referral
and CXL, the cat was treated with topical ofloxacin and
atropine and oral meloxicam. Ofloxacin treatment was dis-
continued and topical oxytetracycline started 2 days before
the CXL procedure due to progressive deepening of the
ulcer. CXL was performed 15 days after initial presenta-
tion because of continued deepening of the ulcer (progres-
sion to 15–20% stromal loss). Topical K-EDTA was
added to the treatment regimen after CXL to help control
collagenolysis.
Cat2, an 11-year-old male castrated European Short-
hair, presented with a rapidly deteriorating opacity and
blepharospasm of the right eye (OD), despite the treat-
ment with neomycin/polymyxin/bacitracin ophthalmic
ointment for 3 days prior to referral. A corneal ulcer with
40% stromal loss, cellular infiltrates, and a malacic center
was observed. No further (peri)ocular abnormalities that
might account for the melting keratitis were observed.
Between4 referral and CXL treatment with topical tobra-
mycin, treatment with oxytetracycline, serum, K-EDTA,
artificial tear gel, and oral doxycycline and meloxicam was
initiated. CXL was performed the next day due to pro-
gressive melting in the center of the ulcer (progression to
50% stromal loss). Medical treatment was continued after-
ward.
Cat3, a 13-year-old female spayed British Shorthair,
presented with a progressively deteriorating opacity and
blepharospasm in OD, despite the treatment with cipro-
floxacin eye drops multiple times per day for four days
prior to referral. On examination, dense cellular infiltrates,
malacic corneal stroma, and stromal loss were observed
across the entire cornea in OD. The exact ulcer depth was
variable across the ulcer, but not recorded at this time-
point. A mild conjunctival hyperemia, presence of thin
superficial mid-peripheral corneal ghost vessels, and mild
superficial corneal stromal fibrosis were observed in OS. A
tentative diagnosis of previous FHV-1-induced keratitis
was made. No further (peri)ocular abnormalities that
might account for the melting keratitis in OD were
observed. Between5 referral and CXL treatment with topi-
cal oxytetracycline, treatment with K-EDTA and serum
and systemic buprenorphine was initiated. CXL was per-
formed the next day due to progressive deepening of the
corneal defect (progression to 75% stroma loss at the
deepest point, observed by the same examiner as the previ-
ous day) and the extension of the lesion. Topical serum
was discontinued and topical ofloxacin and systemic doxy-
cycline were started shortly after the CXL treatment
because of poor patient compliance, concerns regarding
the sterility of the serum, and continued instability of the
mid-peripheral inferior cornea.
Dog 1, a six-year-old male Pug, presented with a his-
tory of distichia removal prior to referral. The additional
history and medical treatment prior to referral were
unknown. A corneal ulcer with 50% stromal loss and mild
cellular infiltrates was observed in OS. Macroblepharon,
lagophthalmos, nasal lower eyelid entropion and trichiasis,
and nasal conjunctival and superficial corneal pigmenta-
tion were observed in both eyes (OU). No further (peri)
ocular abnormalities that might account for the melting
keratitis in OS were observed. Between referral and CXL
treatment with topical neomycin/polymyxin/bacitracin,
treatment with oxytetracycline, K-EDTA and atropine was
initiated. CXL was performed after one day of treatment
because of progressive ulceration and the appearance of
additional stromal ulcers despite the medical therapy.
Medical treatment was continued after CXL.
Dog2, a seven-year-old female spayed Pug, presented
with a two-day history of blepharospasm and progressive
opacification in OD. Initially, the eye was treated with
topical tobramycin/dexamethasone and atropine and with
systemic meloxicam. On day two, a fluorescein-positive
defect was observed, tobramycin/dexamethasone was dis-
continued, and topical ciprofloxacin, trusopt, and vitamin
A were added to the treatment regimen by the referring
veterinarian immediately prior to referral. On examina-
tion, the entire central and mid-peripheral superficial 50%
of the stromal layer was moveable relative to the underly-
ing deeper stroma using a cotton-tipped applicator, and
the corneal surface had started to deform, had lost its nor-
mal regular curvature and was protruding over the lower
eyelid margin. Relatively mild macroblepharon, lagoph-
thalmos, nasal lower eyelid entropion, and trichiasis were
observed in OU, in addition to nasal conjunctival and
superficial corneal pigmentation. No further (peri)ocular
abnormalities that might account for the melting keratitis
in OD were observed. CXL was performed immediately
and treatment with topical ofloxacin, oxytetracycline,
serum and K-EDTA and systemic doxycycline was initi-
ated.
Dog3, a 13-year-old female spayed Samoyed, presented
with a one-month history of corneal problems in OD.
The owner had initiated treatment with topical neomycin/
polymyxin/bacitracin and dexamethasone and had switched
to topical chloramphenicol 1 week prior to presentation
because of increased opacification of the cornea. A corneal
© 2013 American College of Veterinary Ophthalmologists, Veterinary Ophthalmology, 1–11
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ulcer with minimal stromal loss, associated malacic
stroma, and cellular infiltrates was observed in OD. No
further (peri)ocular abnormalities that might account for
the melting keratitis in OD were observed. CXL was per-
formed after a two-day period of medical therapy with
topical oxytetracycline and K-EDTA with no improve-
ment. Medical therapy was continued after CXL.
Medical therapy with topical antibiotics and anticolla-
genases was continued in all patients after CXL treatment
because discontinuation of medical treatment was judged
unethical in light of the unknown efficacy of CXL treat-
ment in dogs and cats. Table 2 contains a comprehensive
view on the medical treatment of the patients in the study.
The CXL procedure
All procedures were performed under standard general,
isoflurane maintained, inhalation anesthesia (Fig. 1). After
the application of a topical anesthetic (oxybuprocaine
0.4% or tetracaine 0.1% drops) to the affected corneas,
the corneal epithelium was removed with a cotton-tipped
applicator within a 7- to 9-mm-diameter zone, depending
on the size of the infiltrate. A cotton-tipped applicator
was also used for a subjective tactile assessment of stromal
stability. The area containing the cellular infiltrate carried
no epithelium due to the inflammatory and melting pro-
cess. After inserting a lid speculum, isoosmolar 0.1% ribo-
flavin drops were administered every 3 min for 30 min.
The riboflavin drops were prepared immediately before
the treatment by mixing 0.5% aqueous riboflavin solution
(vitamin B2; Streuli, Uznach, Switzerland) and a sterile
20% dextran T-500 solution. Successful penetration of
riboflavin through the corneas was confirmed by visualiz-
ing the riboflavin in the anterior chamber with slit-lamp
biomicroscopy. Then, the corneas were irradiated for
30 min with 365-nm wavelength ultraviolet A light
(UV-A), with an irradiance of 3 mW/cm2 (UV-X; Peschke
Meditrade, Cham, Switzerland). The diameter of irradia-
tion was either 9, 10, or 11 mm depending on the size of
the infiltrate and particular care was taken not to irradiate
the corneal limbus as this area contains the corneal epithe-
lial stem cells that are crucial to re-epithelialization of the
corneal surface. During the 30-min irradiation period, the
cornea was moistened every 3 min with isoosmolar 0.1%
riboflavin solution. The UV light was focused on the cor-
neal surface at a distance of 5 cm. The distance was mea-
sured in every patient. The K€ohler’s optics in the UV
device minimizes the variation in UV intensity between 3
and 7 cm of distance to the eye. CXL was performed in
the presence of a certain risk of UV-induced cytotoxicity
to the endothelium in corneas demonstrating significant
loss of corneal stroma.
Post-treatment follow-up
The available follow-up ranged from 2 to 22.5 months
and included slit-lamp examination, fluorescein staining,
and photographic documentation during all re-examina-
tions.
Post-treatment examinations were performed at day 1
and days 4, 7, 14, and 28 after surgery and at various
times during the long-term follow-up.
RESULTS
Cross-linking was used in three cats and three dogs with
unilateral severe corneal melting. Table 1 summarizes the
pre- and postoperative characteristics of all animals: All
cases presented with active corneal melting of unknown
cause, as described in the Materials and Methods section.
Based on the subjective evaluation of stromal stability/
melting activity as described in the Materials and Methods
section (including the presence of cellular infiltrates, the
perceived stability of the stroma via tactile assessment with
a cotton-tipped applicator, the presence of changes in cor-
neal contour and ulcer depth, and the presence of malacic
corneal material in the ulcer area), the stroma was judged
to be stable between 1–20 days post-CXL in all patients.
A stable stroma was observed much earlier in four of six
cases: between 1–2 days after CXL in three cases (Cat1,
Dog1, and Dog2) and in 4 days in another case (Cat2).
CXL as well as the post-treatment period was uneventful
in Cat1, Cat2 (Fig. 2 a–d) and Dog1, and the clinical signs
of corneal melting were markedly reduced immediately
after CXL (see Table 1). In Dog2 (pug, Fig. 3 d–f), in
which keratomalacia affected the superficial stroma of the
entire central and mid-peripheral cornea, the stroma was
judged to be stable on the first day after CXL. However,
this patient did develop significant superficial pigmentation
during the second month after the procedure. The treated
cornea of cat number 3 (Fig. 3 a–c) developed a corneal
sequestrum within the early post-treatment period and
showed spontaneous extrusion within 1 month of develop-
ment. From day 6 on, the stromal instability was confined
Figure 1. Clinical setup of the CXL procedure under general
anesthesia. The irradiation source is placed at a distance of
approximately 5 cm to the eye. The cornea is soaked with riboflavin
that shows fluorescence when irradiated at 365 nm (arrow).
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to the area beneath and immediately surrounding the
developing corneal sequestrum, whereas the rest of the ini-
tial ulcer bed was stable from day 6 onwards. The stroma
of the entire cornea was stable after 12 days. After sponta-
neous extrusion of the sequestrum, granulation tissue was
observed in the underlying stroma. Complete stabilization
of the corneal stroma was observed after 20 days in Dog3.
The corneal edema that was present at initial presentation
did not disappear during the initial healing stages, but
rather deteriorated despite the stabilization of the melting
process. Bullous keratopathy and an epithelial erosion
were observed at 6 weeks after CXL (3 weeks after the
stroma had stabilized). The intensity of the corneal edema
had decreased and the epithelial erosion closed after
2 weeks of topical treatment with 5% NaCl ointment.
Signs of endothelial damage were only observed in Dog3.
Complete closure of the corneal epithelium was observed
in all cases between 7 and 40 days following CXL. Culture
(a) (b) (c) (d)
Figure 2. Pre- and post-CXL-treatment photographs of the ocular adnexa and cornea of Cat2. In this patient, the healing process was
uncomplicated and the long-term outcome excellent. The epithelial defect had closed and the outline of an area with significant loss of stroma
was visible at day 7 (c). At 22 months after CXL treatment, the cornea showed some thinning and minimal superficial stromal fibrosis at the
previous ulcer site (d). 6
(a) (b) (c)
(d) (e) (f)
Figure 3. Pre- and post-CXL-treatment photographs of the ocular adnexa and cornea of Cat3 and Dog2. Cat3 (a–c): The entire corneal surface
area was affected (a) and 75% of the stromal thickness had been lost at the spot where the ulcer was deepest. On day 15 after CXL treatment, a
corneal sequestrum was diagnosed (b, white arrow). In retrospect, this sequestered area of cornea was clearly visible on the pictures taken at
preceding examinations (see A, white arrow). After spontaneous extrusion of the sequestrum, the outcome was excellent, with some loss of
corneal transparency due to moderate corneal fibrosis (c). Dog2 (d–f): In this pug, keratomalacia affected the superficial stroma of the entire
central and mid-peripheral corneal surface. The superficial stroma was moveable relative to the underlying deeper stroma and the corneal surface
had started to deform and lose the normal regular curvature (d). The stroma was judged to be stable on the first day after CXL (e). Slow,
progressive re-epithelialization of the corneal surface was observed during further rechecks and significant superficial corneal pigmentation
developed during the second month after surgery. No changes in pigmentation were observed afterward (f).
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and sensitivity tests were negative for all patients for which
these were submitted (all cats and Dog2).
DISCUSSION
CXL is a technique that was initially developed for the
treatment of progressive keratoconus in humans.2,4,43 Sub-
sequently, the range of indications was expanded to post-
LASIK ectasia,1 bullous keratopathy,5 early Fuchs’ dystro-
phy 6 and, finally, infectious corneal melting.7–11 CXL has
several mechanisms of action that make it an attractive
adjunctive therapy for the treatment of corneal melting.
Firstly, CXL increases the corneal rigidity and resistance
to collagenases through changes in the tertiary structure
of the collagen fibrils.31,44 Secondly, the UV-A-mediated
photoactivation of riboflavin leads to reactive oxygen spe-
cies–induced photooxidative DNA and RNA damage in
viruses, bacteria, fungi, and protozoa.45,46 Martins et al.
and Schrier et al. demonstrated the antimicrobial effect of
CXL against a host of bacterial isolates in vitro.9,11 Inter-
estingly, the combination of UV light and riboflavin has
been used in transfusion medicine for decades to reduce
the microbial and viral load in blood products.47–52 The
use of CXL as sole treatment for experimentally induced
Fusarium keratitis in a rabbit model was described in a
recent paper.53 The number of colony-forming units was
significantly lowered and the clinically and histopathologi-
cally observed inflammatory changes were decreased in
CXL-treated animals compared to untreated controls.
Based on these results, CXL was considered to be a
potentially useful adjuvant treatment, but not a likely pri-
mary treatment for fungal keratitis.
Following the proof of principle published in 2007, sev-
eral groups have published studies in humans where CXL
was used as an adjuvant treatment in cases where conven-
tional therapy had failed to control infectious melting ker-
atitis. In all cases published, CXL led to an arrest of
progression of infectious melting and re-epithelializa-
tion.7,8,39–41 Indeed, in one study, CXL was successfully
used as sole treatment, without the use of antibiotics, to
stabilize corneas with confirmed (13 of 16 cases) and pre-
sumed (3 of 16 cases) bacterial keratitis.42 In light of these
good clinical results, it is possible that CXL might one
day become a primary treatment option for infectious cor-
neal melting in humans. Following the initial basic
research performed in previous animal studies,31,34,35,37,54
we have returned to the animal cornea with the present
study with the aim to adapt the treatment protocol
reported for use on human cases to the small animal cases
included in this clinical study. The authors theorized that
CXL treatment should lead to as positive a result in the
clinical cases included in this study as the clinical out-
comes reported in clinical studies in human subjects. Pro-
gression of corneal melting was arrested in all six cases
and surgical stabilization of the cornea was not necessary
in any of the cases presented in this study. These results
are in agreement with the current basic scientific and clin-
ical literature cited above.7–9,11,31,39–41,44,53 CXL may
therefore be a useful adjunctive therapy for the treatment
of corneal melting in the veterinary field by shifting the
delicate collagenase–anticollagenase balance in the cornea
toward stability in certain patients and preventing a pro-
gression toward further uncontrolled corneal melting.
CXL could not be evaluated as the sole primary treatment
nor as a treatment for infectious corneal melting in the
present study because the animals enrolled were treated
with topical anticollagenolytic medication after CXL and
the presence of infection could not be demonstrated in
any of the cases. CXL as well as the post-treatment period
was uneventful in three cases (Cat1, Cat2, and Dog1).
The other three cases underwent an uneventful CXL pro-
cedure, but a corneal sequestrum, significant superficial
pigmentation, and bullous keratopathy developed in the
early post-treatment period in Cat3, Dog2, and Dog3,
respectively. Nevertheless, although the post-treatment
healing period was prolonged in Cat3 and Dog3, the
long-term outcome was good in all three cases with com-
plications. The corneal sequestrum observed in Cat3
might represent the result of abundant keratocyte apopto-
sis either caused by the CXL procedure itself or by the
extensive keratomalacia covering the entire surface and up
to 75% of the stromal thickness. Keratocyte apoptosis has
previously been identified ultrastructurally in cases of
feline sequestrum and a role for keratocyte apoptosis in
sequestrum formation was hypothesized.55 It is possible
that the area of the cornea that later developed into a
sequestrum had already begun the sequestration process,
as in retrospect this area was already clearly visible in the
pre-operative clinical images (see Fig 3 a). The two pugs
included in this cases series (Dog 1 and Dog2) were diag-
nosed with macroblepharon, lagophthalmos, nasal lower
eyelid entropion, and trichiasis, in addition to nasal con-
junctival and superficial corneal pigmentation in OU.
Chronic keratitis caused by keratoconjunctivitis sicca,56
medial canthal trichiasis, lower nasal eyelid entropion, or
macropalpebral fissure57 is a known stimulus for the devel-
opment of corneal pigmentation and can also be a predis-
posing factor for the development of melting keratitis,
especially in brachycephalic breeds.14 Melting keratitis can
itself lead to corneal pigmentation through the induction
of corneal neovascularization, stromal inflammatory cell
infiltration, and granulation tissue.14 Only one of the two
pugs (Dog2) developed significant progression of the cor-
neal pigmentation in the treated eye in the second month
following CXL treatment. It is therefore not clear whether
the ocular pathology or the performed CXL procedure or
both were significant factors in the development of corneal
pigmentation in this patient.
The presence of a poorly healing erosion combined
with bullous keratopathy in the Samoyed dog (Dog3) was
indicative of endothelial damage. Endothelial decompen-
sation and bullous keratopathy can be caused by breed-
© 2013 American College of Veterinary Ophthalmologists, Veterinary Ophthalmology, 1–11
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related endothelial dystrophy, iris-to-cornea persistent
pupillary membranes, (surgical) trauma, anterior uveitis/
endotheliitis, glaucoma, toxic damage to the endothelium,
age-related endothelial degeneration, and melting kerati-
tis.14 Endothelial dystrophy, iris-to-cornea persistent
pupillary membranes, surgical trauma, and glaucoma were
unlikely causes in this patient due to a lack of ophthalmic
abnormalities consistent with these diagnoses and no his-
tory of prior ocular surgery. Prior external trauma, ante-
rior uveitis/endotheliitis, and toxic damage to the
endothelium could not be ruled out but did not seem
likely due to a lack of a history of prior eye problems
consistent with these diagnoses. The history of a poorly
healing erosion and concurrent white opacity in the cor-
nea and the patient’s age suggested a combination of pre-
existing age-related endothelial degeneration and melting
keratitis as a likely cause for the clinical problems in
Dog3.58 A pre-existing age-related endothelial decompen-
sation may have been subclinical at the time of initial pre-
sentation or may have been missed by the clinician due to
the overlying edematous stroma with cellular infiltrates.
Alternatively, the CXL procedure itself might have led to
the endothelial damage. It is unclear how the CXL proce-
dure would have lead to endothelial damage in this par-
ticular patient. Because the observed pretreatment stromal
loss was minimal (Table 1), the minimal thickness of 300-
400 lm of riboflavin-saturated stroma needed to ensure
shielding of the endothelium from radiation damage
should have been present. Inadequate focusing of the UV
lamp on the corneal surface and subsequent excessive
radiation delivery to deeper structures, which has been
reported as a potential cause,59 also seems unlikely
because the presence of K€ohler’s optics in the UV device
minimizes the variation in UV intensity between 3 and
7 cm of distance to the eye. A second possible cause for
CXL-induced endothelial cell damage is a decrease in
corneal stromal thickness due to inadequate application of
riboflavin drops to the eye and subsequent desiccation
during the riboflavin saturation and/or CXL treatment
period. Repeated application of riboflavin during the
CXL treatment period is not only necessary to minimize
corneal dryness during the procedure but also to avoid
the effects of degradation of active riboflavin molecules
caused by UV-A exposure. If riboflavin is not replenished
during the CXL procedure, UV photon absorption will
decrease and UV depth penetration will increase, poten-
tially exposing the corneal endothelium to harmful levels
of UV radiation.60 However, inadequate riboflavin appli-
cation was unlikely due to surgeon experience and strict
adherence to the safety protocol dictating complete satu-
ration of the corneal stroma with riboflavin, replenish-
ment of riboflavin during the entire procedure, and a
homogeneous 365-nm UV irradiation of 3 mW/cm2 of
cornea.
A minimal corneal stromal thickness of more than
300 lm must be present for effective shielding of the
endothelium and the deeper structures of the eye.34–37
However, corneal thickness could not be monitored dur-
ing this study due to a lack of physical means to perform
ultrasound pachymetry. A stromal loss of 50% was
observed in 3 of 6 animals enrolled in this study (Cat2,
Dog1, and Dog2), and Cat3 had a maximal ulcer depth of
75% of the total corneal thickness (Table 1). It is there-
fore likely that the deepest areas of the ulcers were at risk
for CXL-induced endothelial damage. We decided to per-
form CXL in the presence of a certain risk of UV-induced
cytotoxicity to the endothelium because intervention was
indicated in the face of medical treatment failure and risk
of spontaneous perforation. Conjunctival grafts typically
are the preferred reconstructive surgical technique to sta-
bilize a melting corneal ulcer, as these grafts provide tec-
tonic, antimicrobial, and anticollagenase support through
the provision of fibrovascular tissue in the ulcer site. How-
ever, permanent scarring can be a major disadvantage of
conjunctival grafts.14,61,62 The size of the corneal defects
in two of the patients (Cat3 and Dog2, Fig. 3) would have
necessitated the use of either very large conjunctival pedi-
cle flaps or 360 degree corneal grafts to cover the defects.
Such grafts would likely have blinded the eyes. In this
light, localized endothelial damage potentially caused by
CXL was theorized to pose a lesser overall risk to sight
and the fate of the eye. However, experimental studies in
rabbits 37 have demonstrated that CXL-induced endothe-
lial damage could have caused significant problems,
including chronic corneal edema, breakdown of stroma,
bullous keratopathy with recurring epithelial erosions, and
decreased vision as a result of all of these abnormalities.
This does not seem to be a common problem in clinical
physician-based ophthalmology though.59 Interestingly,
none of the aforementioned four patients with 50% stro-
mal loss or more (Cat2, Cat3, Dog1, and Dog2) developed
any sign of damage to the endothelium. We theorize that
the presence of corneal edema and/or infiltrates in the
ulcer bed caused the stroma to swell, leading to a safe cor-
neal thickness of more than 300 lm. Alternatively, the
remaining endothelial cells in these patients may have
been able to compensate for a relatively small CXL-
induced endothelial cell loss.
Antimicrobial drug resistance of pathogens seems to be
an increasing problem in veterinary ophthalmology.29 The
possibility that an infection could have played a role in
some of our patients could not be excluded completely
based on the fact that false-negative results are a disadvan-
tage of swab testing.20 The treatment of certain drug-
resistant microorganisms may be facilitated by the direct
antimicrobial effect of CXL.9
Despite the fact that half of the patients enrolled into
this pilot study suffered complications during the post-
treatment period, it was not clear whether these complica-
tions were due to the CXL procedure or merely the result
of the disease process that was treated. CXL is not cur-
rently Food and Drug Administration (FDA) approved;
© 2013 American College of Veterinary Ophthalmologists, Veterinary Ophthalmology, 1–11
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however, it is an accepted and approved method of treat-
ment for people in most countries in Europe and other
parts of the world. The use of CXL for various corneal
ectatic diseases is currently under investigation to gain
FDA approval in 21 completed and ongoing registered
clinical trials (http://clinicaltrials.gov/). Although no spe-
cific safety reports have been published yet, a very low rate
or absence of significant, sight-threatening complications
has been reported in these and other published clinical tri-
als in humans.4,63–67 To our knowledge, there are no
papers describing the application of CXL in veterinary
ophthalmology. Basic safety and efficacy data are lacking
for dogs, cats, and horses, which are the most common
species presented to veterinary ophthalmologists. Long-
term complications and side effects of CXL treatment in
domestic animals are not known, but major complications
seem unlikely due to the low complication rates in
humans. Theoretically, as long as riboflavin is allowed to
saturate the corneal stroma, a homogeneous 365-nm UV
irradiation of 3 mW/cm2 is delivered and the irradiated
cornea has a minimal thickness of 350–400 lm, CXL
should be a safe procedure.35
In conclusion, the medical management of corneal melt-
ing in veterinary ophthalmology can be challenging and
demands a time-consuming therapy. Frequently, it is seri-
ously hampered by the often advanced stage of the disease,
relative therapy resistance, and reduced compliance. The
results described in this pilot study suggest that CXL may
represent a cost-efficient and valuable adjunctive therapy
for corneal melting in the veterinary field.
The relatively low cost involved in acquiring the system,
the low cost of treatment, and the ease of performing the
procedure make CXL accessible to the veterinary market.
However, CXL has the potential to do serious harm when
used in unsuitable ways or situations. Further controlled,
masked, prospective clinical studies comparing the efficacy
and complication rate of CXL to those of traditional med-
ical therapy with CXL are therefore needed in order to
evaluate the safety of this promising treatment modality
and to identify indications and contraindications for its
use in veterinary patients.
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